Iron Chelation by Deferoxamine Prevents Renal Interstitial Fibrosis in Mice with Unilateral Ureteral Obstruction
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Renal fibrosis plays an important role in the onset and progression of chronic kidney diseases (CKD). Although several mechanisms underlying renal fibrosis and candidate drugs for its treatment have been identified, the effect of iron chelator on renal fibrosis remains unclear. In the present study, we examined the effect of an iron chelator, deferoxamine (DFO), on renal fibrosis in mice with surgically induced unilateral ureter obstruction (UUO). Mice were divided into 4 groups: UUO with vehicle, UUO with DFO, sham with vehicle, and sham with DFO. One week after surgery, augmented renal tubulointerstitial fibrosis and the expression of collagen I, III, and IV increased in mice with UUO; these changes were suppressed by DFO treatment. Similarly, UUO-induced macrophage infiltration of renal interstitial tubules was reduced in UUO mice treated with DFO. UUO-induced expression of inflammatory cytokines and extracellular matrix proteins was abrogated by DFO treatment. DFO inhibited the activation of the transforming growth factor-β1 (TGF-β1)-Smad3 pathway in UUO mice. UUO-induced NADPH oxidase activity and p22(phox) expression were attenuated by DFO. In the kidneys of UUO mice, divalent metal transporter 1, ferroportin, and ferritin expression was higher and transferrin receptor expression was lower than in sham-operated mice. Increased renal iron content was observed in UUO mice, which was reduced by DFO treatment. These results suggest that iron reduction by DFO prevents renal tubulointerstitial fibrosis by regulating TGF-β-Smad signaling, oxidative stress, and inflammatory responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The authors concluded that in mice iron reduction by deferoxamine may prevent renal interstitial fibrosis by regulating TGF-beta/Smad signaling, oxidative stress, and inflammatory responses [67].”
From The utility of iron chelators in the management of inflammatory disorders (2015) · cites this paper as [67]
In the citing paper
“After a surgically induced unilateral ureter obstruction (UUO), mice treated with DFO showed significantly less fibrotic progression, less interstitial macrophage infiltration, and thereby a reduced expression of IL-1β and MCP-1 and a suppressed UUO-induced accumulation of myofibroblasts, compared with untreated mice.”
From The utility of iron chelators in the management of inflammatory disorders (2015) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Myofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290 · cited 1×
“In addition, activated fibroblasts (also known as myofibroblasts) that express aSMA are a major source of extracellular matrix production [44].”
BackgroundThe Transforming Growth Factor-beta Family
Massague, J. (1990) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.06.110190.003121 · Cited by 3,015 · cited 1×
“Indeed, TGF-b1 is a well-known major profibrotic stimulator of collagen and extracellular matrix production in a variety of cell types [38].”
BackgroundMassagué, J. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043051 · Cited by 1,899
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals
Smith, M. A., Harris, P. L. R., Sayre, L. M., & Perry, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9866 · Cited by 1,355 · cited 1×
“[9,10], and that iron reduction therapy can ameliorate these disorders [7,8,11,12].”
BackgroundHypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition
Higgins, D. F., Kimura, K., Bernhardt, W. M., Shrimanker, N., Akai, Y., Hohenstein, B., Saito, Y., Johnson, R. S., Kretzler, M., Cohen, C. D., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30487 · Cited by 976
Ferritins: A family of molecules for iron storage, antioxidation and more
Arosio, P., Ingrassia, R., & Cavadini, P. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.09.004 · Cited by 886 · cited 1×
“Ferritin, an intracellular iron storage protein, reduces intracellular free iron levels, thereby suppressing catalysis of the Fenton reaction [61].”
BackgroundSato, M., Muragaki, Y., Saika, S., Roberts, A. B., & Ooshima, A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19270 · Cited by 831 · cited 2×
“Similar to its role in fibrosis, TGF-b1-Smad3 signaling is a key mediator for triggering EMT in vivo [42].”
BackgroundOberg, B. P., McMenamin, E., Lucas, F. L., McMonagle, E., Morrow, J., Ikizler, T. A. L. P., & Himmelfarb, J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00465.x · Cited by 781 · cited 1×
“Oxidative stress is considered a contributing factor in the progression of CKD, including renal fibrosis [49].”
BackgroundWang, G., & Semenza, G. (1993) · Blood · doi:10.1182/blood.v82.12.3610.3610 · Cited by 766
Labile iron pool: the main determinant of cellular response to oxidative stress
Kruszewski, M. (2003) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2003.08.004 · Cited by 533 · cited 1×
“catalytic reactions [4], which in turn cause tissue damage.”
BackgroundLong-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major
Olivieri, N. F., Brittenham, G. M., McLaren, C. E., Templeton, D. M., Cameron, R. G., McClelland, R. A., Burt, A. D., & Fleming, K. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390701 · Cited by 420 · cited 1×
“In these patients, the progression of liver fibrosis can be delayed or prevented by iron chelation therapy [30–32].”
BackgroundHypoxia promotes fibrogenesis in human renal fibroblasts
Norman, J. T., Clark, I. M., & Garcia, P. L. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00419.x · Cited by 358 · cited 1×
“DFO also increases collagen I and tissue inhibitor metalloproteinase 1 mRNA levels in vitro [27].”
BackgroundBarry, M., Flynn, D. M., Letsky, E. A., & Risdon, R. A. (1974) · BMJ · doi:10.1136/bmj.2.5909.16 · Cited by 326 · cited 1×
“In these patients, the progression of liver fibrosis can be delayed or prevented by iron chelation therapy [30–32].”
BackgroundMiyajima, A., Chen, J., Lawrence, C., Ledbetter, S., Soslow, R. A., Stern, J., Jha, S., Pigato, J., Lemer, M. L., Poppas, D. P., et al. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00414.x · Cited by 321 · cited 1×
“In the kidney, TGF-b1 expression increased with UUO [40], and treatment with a neutralizing antibody to TGF-b1 ameliorated UUO-induced renal interstitial fibrosis [41].”
BackgroundNeufeld, E. J. (2006) · Blood · doi:10.1182/blood-2006-02-002394 · Cited by 315 · cited 1×
“Deferoxamine (DFO), a bacteria-derived siderophore, chelates iron by binding iron in the blood and excreting it as a DFO-iron complex in urine or stool [24].”
BackgroundKaneto, H., Morrissey, J., & Klahr, S. (1993) · Kidney International · doi:10.1038/ki.1993.246 · Cited by 292 · cited 1×
“In the kidney, TGF-b1 expression increased with UUO [40], and treatment with a neutralizing antibody to TGF-b1 ameliorated UUO-induced renal interstitial fibrosis [41].”
BackgroundThe State of Chronic Kidney Disease, ESRD, and Morbidity and Mortality in the First Year of Dialysis
Collins, A. J., Foley, R. N., Gilbertson, D. T., & Chen, S.-C. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05980809 · Cited by 287 · cited 1×
“CKD worsens morbidity and mortality in the general population [1,2].”
BackgroundFibroblast activation and myofibroblast generation in obstructive nephropathy
Grande, M. T., & López-Novoa, J. M. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.74 · Cited by 265 · cited 1×
“The epithelial mesenchymal transition (EMT) contributes to the development of renal interstitial fibrosis induced by UUO [47].”
BackgroundExpression of NADH/NADPH Oxidase p22 phox in Human Coronary Arteries
Azumi, H., Inoue, N., Takeshita, S., Rikitake, Y., Kawashima, S., Hayashi, Y., Itoh, H., & Yokoyama, M. (1999) · Circulation · doi:10.1161/01.cir.100.14.1494 · Cited by 256 · cited 1×
“Furthermore, p22 expression was colocalized in F4/80or CD 68-positive cells that were obtained from the fat of diabetic and obese mice or from human atherosclerotic coronary arteries [16,54].”
BackgroundFacchini, F. S., Hua, N. W., & Stoohs, R. A. (2002) · Gastroenterology · doi:10.1053/gast.2002.32403 · Cited by 233 · cited 1×
“Similarly, iron reduction by phlebotomy or a low-iron diet suppresses hepatic fibrosis in patients with hepatitis C [33–35] and suppresses nonalcohol fatty liver disease [36].”
BackgroundMechanisms of tubulointerstitial fibrosis
Iwano, M., & Neilson, E. G. (2004) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200405000-00003 · Cited by 223
Inazaki, K., Kanamaru, Y., Kojima, Y., Sueyoshi, N., Okumura, K., Kaneko, K., Yamashiro, Y., Ogawa, H., & Nakao, A. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00779.x · Cited by 217 · cited 1×
“Disruption of Smad3 diminished UUO-induced renal tubulointerstitial fibrosis, suggesting that Smad3 plays a crucial role in the development of fibrosis in kidney diseases [42,43].”
BackgroundIron Promotes the Toxicity of Amyloid β Peptide by Impeding Its Ordered Aggregation
Liu, B., Moloney, A., Meehan, S., Morris, K., Thomas, S. E., Serpell, L. C., Hider, R., Marciniak, S. J., Lomas, D. A., & Crowther, D. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.158980 · Cited by 216 · cited 1×
“[9,10], and that iron reduction therapy can ameliorate these disorders [7,8,11,12].”
BackgroundMetal Chelation as a Potential Therapy for Alzheimer's Disease
CUAJUNGCO, M. P., FAGÉT, K. Y., HUANG, X., TANZI, R. E., & BUSH, A. I. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06938.x · Cited by 215
Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders
Camaschella, C. (2005) · Blood · doi:10.1182/blood-2005-05-1857 · Cited by 199 · cited 1×
“cardiomyopathy, liver cirrhosis, and diabetes mellitus following ectopic iron accumulation in the heart, liver, and pancreas, respectively [6].”
BackgroundInfluentialThe origin of interstitial myofibroblasts in chronic kidney disease
Grgic, I., Duffield, J. S., & Humphreys, B. D. (2012) · Pediatric Nephrology · doi:10.1007/s00467-011-1772-6 · Cited by 197 · cited 1×
“However, several studies have shown that EMT does not result in the generation of interstitial myofibroblasts in fibrotic renal disease models, and therefore the role of EMT has remained controversial [48].”
BackgroundHarmatz, P., Butensky, E., Quirolo, K., Williams, R., Ferrell, L., Moyer, T., Golden, D., Neumayr, L., & Vichinsky, E. (2000) · Blood · doi:10.1182/blood.v96.1.76 · Cited by 194
VIELHAUER, V., ANDERS, H.-J., MACK, M., CIHAK, J., STRUTZ, F., STANGASSINGER, M., LUCKOW, B., GRO[Combining Diaeresis]NE, H.-J., & SCHLO[Combining Diaeresis]NDORFF, D. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1261173 · Cited by 177
Cairo, G., Recalcati, S., Pietrangelo, A., & Minotti, G. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00825-0 · Cited by 176 · cited 1×
“other complexes under normal physiological conditions [5].”
Fuller, S. D., & Simons, K. (1986) · The Journal of cell biology · doi:10.1083/jcb.103.5.1767 · Cited by 175 · cited 8×
“The following antibodies were used: antiF4/80 (1:500), anti-aSMA (1:200), anti-fibronectin (1:100), antip22phox (1:100), anti-TfR (1:200), anti-DMT1 (1:100), anti-FPN (1:100), anti-FTH (1:100), and anti-FTL (1:100).”
BackgroundInfluentialCooksey, R. C., Jones, D., Gabrielsen, S., Huang, J., Simcox, J. A., Luo, B., Soesanto, Y., Rienhoff, H., Dale Abel, E., & McClain, D. A. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00022.2010 · Cited by 168
Increased oxidative stress in mouse kidneys with unilateral ureteral obstruction
Kawada, N., Moriyama, T., Ando, A., Fukunaga, M., Miyata, T., Kurokawa, K., Imai, E., & Hori, M. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00612.x · Cited by 146 · cited 1×
“UUO, a widely used experimental model of renal fibrosis, induces oxidative stress; oxidative stress plays a crucial role in the pathogenesis of UUO in the kidney [50].”
BackgroundEstrogen Regulates Hepcidin Expression via GPR30-BMP6-Dependent Signaling in Hepatocytes
Ikeda, Y., Tajima, S., Izawa-Ishizawa, Y., Kihira, Y., Ishizawa, K., Tomita, S., Tsuchiya, K., & Tamaki, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040465 · Cited by 140 · cited 1×
“Metallo Assay kit (AKJ Global Technology, Chiba, Japan) as previously described [23,29].”
MethodSelf-citationCellular localization of divalent metal transporter DMT-1 in rat kidney
Ferguson, C. J., Wareing, M., Ward, D. T., Green, R., Smith, C. P., & Riccardi, D. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.5.f803 · Cited by 135 · cited 7×
“The following antibodies were used: antiF4/80 (1:500), anti-aSMA (1:200), anti-fibronectin (1:100), antip22phox (1:100), anti-TfR (1:200), anti-DMT1 (1:100), anti-FPN (1:100), anti-FTH (1:100), and anti-FTL (1:100).”
BackgroundInfluentialTajima, S., Ikeda, Y., Sawada, K., Yamano, N., Horinouchi, Y., Kihira, Y., Ishizawa, K., Izawa-Ishizawa, Y., Kawazoe, K., Tomita, S., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00033.2011 · Cited by 112 · cited 7×
“Furthermore, p22 expression was colocalized in F4/80or CD 68-positive cells that were obtained from the fat of diabetic and obese mice or from human atherosclerotic coronary arteries [16,54].”
BackgroundMethodSelf-citationAlvarez, R. J., Sun, M. J., Haverty, T. P., Iozzo, R. V., Myers, J. C., & Neilson, E. G. (1992) · Kidney International · doi:10.1038/ki.1992.3 · Cited by 109 · cited 1×
“Furthermore, fibroblasts were activated by various cytokines including TGF-b [45], and TGF-b signaling was inhibited by DFO.”
BackgroundInfusion of IL-10–expressing cells protects against renal ischemia through induction of lipocalin-2
Jung, M., Solà, A., Hughes, J., Kluth, D., Vinuesa, E., Viñas, J. L., Pérez-Ladaga, A., & Hotter, G. (2012) · Kidney International · doi:10.1038/ki.2011.446 · Cited by 104
Expression of the iron transporter DMT1 in kidney from normal and anemic mk mice
Canonne‐Hergaux, F., & Gros, P. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00405.x · Cited by 103 · cited 7×
“The following antibodies were used: antiF4/80 (1:500), anti-aSMA (1:200), anti-fibronectin (1:100), antip22phox (1:100), anti-TfR (1:200), anti-DMT1 (1:100), anti-FPN (1:100), anti-FTH (1:100), and anti-FTL (1:100).”
BackgroundInfluentialIron restriction improves type 2 diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats
Minamiyama, Y., Takemura, S., Kodai, S., Shinkawa, H., Tsukioka, T., Ichikawa, H., Naito, Y., Yoshikawa, T., & Okada, S. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00620.2009 · Cited by 90 · cited 1×
“obesity [16], and diabetes [17,18].”
Sugiyama, H., Kobayashi, M., Wang, D.-H., Sunami, R., Maeshima, Y., Yamasaki, Y., Masuoka, N., Kira, S., & Makino, H. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi045 · Cited by 83 · cited 2×
“showed that UUO-induced p22 was expressed in renal tubules [51].”
BackgroundLong term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C
Yano, M., Hayashi, H., Wakusawa, S., Sanae, F., Takikawa, T., Shiono, Y., Arao, M., Ukai, K., Ito, H., Watanabe, K., et al. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05436.x · Cited by 82
Wolff, N. A., Liu, W., Fenton, R. A., Lee, W.-K., Thévenod, F., & Smith, C. P. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00985.x · Cited by 70 · cited 8×
“The following antibodies were used: antiF4/80 (1:500), anti-aSMA (1:200), anti-fibronectin (1:100), antip22phox (1:100), anti-TfR (1:200), anti-DMT1 (1:100), anti-FPN (1:100), anti-FTH (1:100), and anti-FTL (1:100).”
BackgroundInfluentialIron Overload Augments Angiotensin II–Induced Cardiac Fibrosis and Promotes Neointima Formation
Ishizaka, N., Saito, K., Mitani, H., Yamazaki, I., Sata, M., Usui, S.-I., Mori, I., Ohno, M., & Nagai, R. (2002) · Circulation · doi:10.1161/01.cir.0000031161.77536.02 · Cited by 65 · cited 4×
“The preventive effects of DFO on the progression of obesity [16] and AngII-induced cardiovascular fibrosis have been demonstrated [13,14].”
BackgroundInfluentialHayashi, H., Takikawa, T., Nishimura, N., & Yano, M. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80278-9 · Cited by 59
Ishizaka, N., Saito, K., Mori, I., Matsuzaki, G., Ohno, M., & Nagai, R. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000181763.57495.2b · Cited by 55 · cited 4×
“The preventive effects of DFO on the progression of obesity [16] and AngII-induced cardiovascular fibrosis have been demonstrated [13,14].”
BackgroundInfluentialDietary Iron Restriction Prevents Hypertensive Cardiovascular Remodeling in Dahl Salt-Sensitive Rats
Naito, Y., Hirotani, S., Sawada, H., Akahori, H., Tsujino, T., & Masuyama, T. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.159681 · Cited by 54 · cited 3×
“Indeed, tissue iron concentration are also augmented in the aorta and heart after AngII infusion [13,14], aorta of Dahl salt-sensitive rats [15], and the kidneys of db/db mice [23].”
BackgroundDietary iron restriction inhibits progression of diabetic nephropathy in db/db mice
Ikeda, Y., Enomoto, H., Tajima, S., Izawa-Ishizawa, Y., Kihira, Y., Ishizawa, K., Tomita, S., Tsuchiya, K., & Tamaki, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00473.2012 · Cited by 53 · cited 8×
“Expression of these iron transporters was altered in diabetic nephropathy [23,59], 5/6”
BackgroundMethodSelf-citationLi, L., & Frei, B. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000245820.34238.da · Cited by 49
Ishizaka, N., Saito, K., FURUTA, K., Matsuzaki, G., Koike, K., Noiri, E., & Nagai, R. (2007) · Hypertension Research · doi:10.1291/hypres.30.195 · Cited by 44
Li, L., & Frei, B. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.183210 · Cited by 42 · cited 1×
“Our study group and others have demonstrated that iron chelators suppress oxidative stress by inhibiting p22 expression and NADPH oxidase activity in diabetic obese mice [16], mice with diabetic nephropathy [23], a murine model with local inflammation [52], and in endothelial cells [53].”
BackgroundNaito, Y., Fujii, A., Sawada, H., Hirotani, S., Iwasaku, T., Eguchi, A., Ohyanagi, M., Tsujino, T., & Masuyama, T. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283581a64 · Cited by 39 · cited 4×
“inhibiting mineralocorticoid receptor signaling in rats with CKD modeled with 5/6 nephrectomy [21,22].”
BackgroundInfluentialFerguson, C. J., Wareing, M., Delannoy, M., Fenton, R. A., McLarnon, S., Ashton, N., Cox, A. G., McMahon, R. F., Garrick, L. M., Green, R., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00274.x · Cited by 38 · cited 1×
“nephrectomy [21], the anemic kidney [60], and kidneys with AngII infusion [20], indicating an alteration in renal iron metabolism in these diseases.”
BackgroundChronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome
Sartori, M., Andorno, S., Rigamonti, C., & Boldorini, R. (2001) · Digestive and Liver Disease · doi:10.1016/s1590-8658(01)80072-4 · Cited by 34 · cited 1×
“Similarly, iron reduction by phlebotomy or a low-iron diet suppresses hepatic fibrosis in patients with hepatitis C [33–35] and suppresses nonalcohol fatty liver disease [36].”
BackgroundSaito, K., Ishizaka, N., Aizawa, T., Sata, M., Iso-o, N., Noiri, E., Mori, I., Ohno, M., & Nagai, R. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00679.2004 · Cited by 33
Naito, Y., Fujii, A., Sawada, H., Hirotani, S., Iwasaku, T., Okuhara, Y., Eguchi, A., Ohyanagi, M., Tsujino, T., & Masuyama, T. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328360381d · Cited by 33 · cited 1×
“inhibiting mineralocorticoid receptor signaling in rats with CKD modeled with 5/6 nephrectomy [21,22].”
BackgroundSaito, K., Ishizaka, N., AIZAWA, T., Sata, M., Iso-O, N., Noiri, E., Ohno, M., & Nagai, R. (2004) · Hypertension Research · doi:10.1291/hypres.27.599 · Cited by 32 · cited 2×
“They also reported that iron chelation suppressed AngII-induced TGF-b1 upregulation in the kidney [19] and heart [37].”
BackgroundAltered expression of iron transport proteins in streptozotocin-induced diabetic rat kidney
Ward, D. T., Hamilton, K., Burnand, R. C., Smith, C. P., Tomlinson, D. R., & Riccardi, D. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.01.008 · Cited by 28 · cited 1×
“Expression of these iron transporters was altered in diabetic nephropathy [23,59], 5/6”
BackgroundAdditional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C.
Kimura, F., Hayashi, H., Yano, M., Yoshioka, K., Matsumura, T., Fukuda, T., Shigeto, N., Yamahara, S., Koushi, F., Mishima, Y., et al. (2005) · PubMed · Cited by 11
Engelfriet, C. P., Harmatz, P., Butensky, E., & Quirolo, K. C. (2000) · Vox Sanguinis · doi:10.1046/j.1423-0410.2000.79402651.x · Cited by 5
(2001) · PubMed
(1994) · PubMed
Research works printed but not linked: 1
- G Cairo, 2002, The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage, Free Radic Biol Med, 32, 1237
Cited by
Bayır, H., Dixon, S. J., Tyurina, Y. Y., Kellum, J. A., & Kagan, V. E. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00689-x · Cited by 331
The multifaceted role of iron in renal health and disease
van Swelm, R. P. L., Wetzels, J. F. M., & Swinkels, D. W. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0197-5 · Cited by 275
Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis
Handa, P., Thomas, S., Morgan-Stevenson, V., Maliken, B. D., Gochanour, E., Boukhar, S., Yeh, M. M., & Kowdley, K. V. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.3a0318-108r · Cited by 217
COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy
Perricone, C., Bartoloni, E., Bursi, R., Cafaro, G., Guidelli, G. M., Shoenfeld, Y., & Gerli, R. (2020) · Immunologic Research · doi:10.1007/s12026-020-09145-5 · Cited by 208
Current health risk assessment practice for dietary cadmium: Data from different countries
Satarug, S., Vesey, D. A., & Gobe, G. C. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.06.013 · Cited by 203
Metadata
- Authors
- Ikeda, Y., Ozono, I., Tajima, S., Imao, M., Horinouchi, Y., Izawa-Ishizawa, Y., Kihira, Y., Miyamoto, L., Ishizawa, K., Tsuchiya, K., & Tamaki, T.
- Affiliations
- Tokushima University (JP)
- Corresponding author
- Ikeda, Yasumasa
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-19
- Volume
- 9
- Issue
- 2
- Pages
- e89355
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3929716
- OpenAlex
- W1977079786
- Cited by
- 98
- References
- 62
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 10 · 2023: 7 · 2022: 11 · 2021: 7 · 2020: 9 · 2019: 10 · 2018: 6 · 2017: 6 · 2016: 4 · 2015: 7 · 2014: 1
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Osaka Foundation for Promotion of Fundamental Medical Research
- Japan Society for the Promotion of Science (24790254, 24591203, 25860063)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- deferoxamine, iron chelation, tubulointerstitial fibrosis, unilateral ureteral obstruction, chronic kidney disease, TGF-β1/Smad3 signaling, oxidative stress, NADPH oxidase, macrophage infiltration, inflammation, extracellular matrix, iron metabolism, ferroportin, ferritin, transferrin receptor, DMT1
- MeSH terms
- Animals, Deferoxamine, Fibrosis, Immunohistochemistry, Iron Chelating Agents, Kidney Diseases, Ureteral Obstruction, Blotting, Western, Signal Transduction, Chelation Therapy, Transforming Growth Factor beta, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.